Drinkhouse Macy, Brooks Marjory B, Stefanovski Darko, Marryott Kimberly, Callan Mary Beth
Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Comparative Coagulation Section-Animal Health Diagnostic Center, Cornell University, Ithaca, New York.
J Vet Intern Med. 2019 Jan;33(1):124-131. doi: 10.1111/jvim.15376. Epub 2018 Dec 11.
Cryoprecipitate (CRYO) is a plasma component containing high concentrations of factor VIII (FVIII), von Willebrand factor (VWF), and fibrinogen. Because Greyhounds are reported to have lower plasma VWF and fibrinogen concentrations, their plasma may not yield high potency CRYO.
To determine if plasma hemostatic protein concentration is a good predictor of CRYO potency and if a difference exists in quality of CRYO prepared from Greyhounds versus non-Greyhounds.
Twenty Greyhounds and 20 non-Greyhounds.
A 450 mL unit of blood was collected from each donor, centrifuged to prepare fresh frozen plasma (FFP), and processed to CRYO. Aliquots of FFP and CRYO were analyzed for FVIII, VWF, and fibrinogen content and factor recovery.
A positive correlation was found among donor plasma FVIII, VWF and fibrinogen concentration, and CRYO factor content (P < .001). Mean recovery was highest for VWF (67%), followed by fibrinogen (47%), and FVIII (37%). No breed difference was found in mean CRYO FVIII content, but CRYO VWF and fibrinogen were lower in Greyhounds (P = .004 and P < .001, respectively). No difference was found between Greyhounds and non-Greyhounds for the number of CRYO units meeting human blood banking standards.
Factor concentration in FFP is associated with CRYO potency, suggesting that prescreening of blood donors may enhance CRYO quality. Despite lower VWF and fibrinogen content, CRYO prepared from Greyhounds is acceptable based on blood banking standards for humans, indicating that Greyhound FFP does not need to be excluded from CRYO production.
冷沉淀(CRYO)是一种血浆成分,含有高浓度的凝血因子VIII(FVIII)、血管性血友病因子(VWF)和纤维蛋白原。据报道,灵缇犬的血浆VWF和纤维蛋白原浓度较低,其血浆可能无法产生高效能的冷沉淀。
确定血浆止血蛋白浓度是否是冷沉淀效能的良好预测指标,以及从灵缇犬与非灵缇犬制备的冷沉淀质量是否存在差异。
20只灵缇犬和20只非灵缇犬。
从每个供体采集450毫升单位的血液,离心制备新鲜冰冻血浆(FFP),并加工成冷沉淀。对FFP和冷沉淀的等分试样进行FVIII、VWF和纤维蛋白原含量及因子回收率分析。
供体血浆FVIII、VWF和纤维蛋白原浓度与冷沉淀因子含量之间存在正相关(P <.001)。VWF的平均回收率最高(67%),其次是纤维蛋白原(47%)和FVIII(37%)。冷沉淀FVIII平均含量未发现品种差异,但灵缇犬的冷沉淀VWF和纤维蛋白原含量较低(分别为P =.004和P <.001)。符合人类血库标准的冷沉淀单位数量在灵缇犬和非灵缇犬之间未发现差异。
FFP中的因子浓度与冷沉淀效能相关,提示对献血者进行预筛选可能提高冷沉淀质量。尽管VWF和纤维蛋白原含量较低,但根据人类血库标准,从灵缇犬制备的冷沉淀是可接受的,这表明灵缇犬的FFP无需被排除在冷沉淀生产之外。